Loading...
XETR
SBS
Market cap364mUSD
Jun 13, Last price  
24.45EUR
1D
-0.58%
1Q
-8.01%
Jan 2017
-43.55%
Name

Stratec SE

Chart & Performance

D1W1MN
No data to show
P/E
22.75
P/S
1.13
EPS
1.07
Div Yield, %
2.13%
Shrs. gr., 5y
0.21%
Rev. gr., 5y
6.88%
Revenues
262m
-4.63%
39,207,23248,415,0910067,527,00079,589,273106,731,999122,196,813122,424,000127,950,000144,860,000146,886,000184,911,000209,764,000187,819,000221,641,000250,099,000287,335,000274,625,000261,911,000
Net income
13m
-55.29%
2,777,9074,412,559009,991,00011,673,58613,039,16315,281,66013,973,00015,478,00019,768,00022,084,00019,572,00025,635,0008,969,00014,440,00025,175,00039,958,00029,223,00013,067,000
CFO
19m
+88.98%
2,406,0001,308,0008,827,0009,567,8804,690,00010,878,0001,448,00010,707,0002,720,00023,837,00039,752,00026,033,00016,256,00029,981,00011,950,00021,262,00031,849,00063,473,00010,279,00019,425,000
Dividend
May 20, 20240.55 EUR/sh

Profile

Stratec SE, together with its subsidiaries, designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally. It operates through three segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment designs and manufactures automated analyzer systems, including service parts and consumables for clinical diagnostics and biotechnology customers. The Diatron segment offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications. The Smart Consumables segment develops and manufactures smart consumables in the fields of diagnostics, life sciences, and medical technologies. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.
URL
https://www.stratec.com/
IPO date
Aug 25, 1998
Employees
1,512
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
261,911
-4.63%
274,625
-4.42%
Cost of revenue
237,739
232,261
Unusual Expense (Income)
NOPBT
24,172
42,364
NOPBT Margin
9.23%
15.43%
Operating Taxes
5,162
9,865
Tax Rate
21.36%
23.29%
NOPAT
19,010
32,499
Net income
13,067
-55.29%
29,223
-26.87%
Dividends
(11,790)
(11,521)
Dividend yield
Proceeds from repurchase of equity
1,744
BB yield
Debt
Debt current
47,035
7,084
Long-term debt
110,667
93,591
Deferred revenue
24,181
15,477
Other long-term liabilities
21,182
7,120
Net debt
120,587
74,468
Cash flow
Cash from operating activities
19,425
10,279
CAPEX
(8,342)
(19,019)
Cash from investing activities
(44,155)
(18,997)
Cash from financing activities
35,442
(14,105)
FCF
(30,254)
(5,632)
Balance
Cash
34,215
24,072
Long term investments
2,900
2,135
Excess cash
24,019
12,476
Stockholders' equity
176,866
190,074
Invested Capital
383,088
311,181
ROIC
5.48%
11.00%
ROCE
5.79%
12.72%
EV
Common stock shares outstanding
12,159
12,173
Price
Market cap
EV
EBITDA
41,865
59,295
EV/EBITDA
Interest
3,992
1,898
Interest/NOPBT
16.51%
4.48%